Business
AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen® (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue
OCALA, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the European Patent Office has officially granted AIM’s European Patent No. 4,096,675, titled “Compositions for Treating LONG COVID,” covering compositions of matter of AIM’s proprietary dsRNAs including, for example, Ampligen® (rintatolimod) for use in the treatment of Long COVID. “While AIM’s immediate and primary focus is to build upon the continued positive re
About this update from Aim Immunotech Inc.
[{"type":"image","alt":"AIM ImmunoTech Inc.","displaySize":"","headline":null,"caption":"AIM ImmunoTech Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":160,"url":"https://media.zenfs.com/en/globenewswire.com/c64a717b389cb0d8a4c8889b41b5cabd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ExfZBbISk6KxGeFYkBNhew--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c64a717b389cb0d8a4c8889b41b5cabd","width":300,"height":160}},"lazy":false},{"type":"text","content":"OCALA, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the European Patent Office has officially granted AIM’s European Patent No. 4,096,675, titled “Compositions for Treating LONG COVID,” covering compositions of matter of AIM’s proprietary dsRNAs including, for example, Ampligen® (rintatolimod) for use in the treatment of Long COVID.","length":426,"tagName":"p"},{"type":"text","content":"“While AIM’s immediate and primary focus is to build upon the continued positive results from our late-stage pancreatic cancer clinical program, this new European patent in Long COVID strengthens our intellectual property portfolio while providing additional validation of our belief in Ampligen’s potential as a broad-spectrum immunotherapy,” commented AIM CEO Thomas K. Equels.","length":379,"tagName":"p"},{"type":"text","content":"Ampligen is AIM’s RNA product candidate designed to modulate the immune system. Data from in vitro, pre-clinical and clinical experiments suggest that Ampligen has a broad-spectrum, early-onset antiviral effect by stimulating a strong innate immune response. The Company has conducted Ampligen experiments in SARS-CoV-1 showing a significant decrease in viral replication. Since the viral genome of SARS-CoV-1 is highly homologous (>90%) to SARS-CoV-2 structural proteins, this indicates that Ampligen may have similar antiviral activity in Long COVID. Additionally, AIM conducted a Phase 2 study (“AMP-518”) evaluating the efficacy and safety of Ampligen as a potential therapeutic for people with the post-COVID condition of fatigue (i.e., Long COVID) and reported positive topline results demonstrating Ampligen to be generally well tolerated and efficacy results offering evidence that Ampligen may re...